Fenofibrate
Active ingredient: Fenofibrate
In short: Fenofibrate tablets are indicated as adjunctive therapy to diet: • to reduce triglyceride (TG) levels in adults with severe hypertriglyceridemia (TG greater than or equal to 500 mg/dL). • to reduce elevated low-density lipoprotein cholesterol (LDL-C) in adults with primary hyperlipidemia when use of
What is Fenofibrate used for?
Fenofibrate tablets are indicated as adjunctive therapy to diet:
•
to reduce triglyceride (TG) levels in adults with severe hypertriglyceridemia (TG greater than or equal to 500 mg/dL).
•
to reduce elevated low-density lipoprotein cholesterol (LDL-C) in adults with primary hyperlipidemia when use of recommended LDL-C lowering therapy is not possible.
Limitations of Use
•
Markedly elevated levels of serum TG (e.g. > 2,000 mg/dL) may increase the risk of developing pancreatitis. The effect of fenofibrate therapy on reducing this risk has not been determined .
•
Fenofibrate did not reduce coronary heart disease morbidity and mortality in two large, randomized controlled trials of patients with type 2 diabetes mellitus .
Fenofibrate dosage
•Assess lipid levels before initiating therapy. Identify other causes (e.g., diabetes mellitus, hypothyroidism, or medications) of high TG levels and manage as appropriate.
•Patients should be placed on an appropriate lipid-lowering diet before receiving fenofibrate tablets, and should continue this diet during treatment with fenofibrate tablets.
•
In patients with diabetes and fasting chylomicronemia, improve glycemic control prior to considering starting fenofibrate tablets.
•
Severe hypertriglyceridemia:
oThe recommended dosage of fenofibrate tablets is 48 mg or 145 mg orally once daily.
oDosage should be individualized according to patient response, and should be adjusted if necessary following repeat lipid determinations at 4 to 8 week intervals.
•
Primary hyperlipidemia:
oThe recommended dosage of fenofibrate tablets is 145 mg orally once daily.
•Administer fenofibrate tablets as a single dose at any time of day, with or without food.
•
Advise patients to swallow fenofibrate tablets whole. Do not crush, break, dissolve, or chew tablets.
•Assess TG when clinically appropriate, as early as 4 to 8 weeks after initiating fenofibrate tablets. Discontinue fenofibrate tablets in patients who do not have an adequate response after 2 months of treatment.
•
If a dose is missed, advise patients not to take an extra dose. Resume treatment with the next dose.
•
Advise patients to take fenofibrate tablets at least 1 hour before or 4 hours to 6 hours after a bile acid binding resin to avoid impeding its absorption.
•
Assess renal function prior to initiation of fenofibrate tablets and periodically thereafter .
•Treatment with fenofibrate tablets should be initiated at a dosage of 48 mg orally once daily in patients with mild to moderately impaired renal function (eGFR 30 to <60 mL/min/1.73m2), and increased only after evaluation of the effects on renal function and TG levels at this dosage.
•
Fenofibrate tablets are contraindicated in patients with severe renal impairment (eGFR <30 mL/min/1.73m2), including those with end-stage renal disease (ESRD) and those receiving dialysis .
Dosage selection for geriatric patients should be made on the basis of renal function .
How to take Fenofibrate — instructions & advice from the label
Hepatotoxicity
Inform patients that fenofibrate tablets may cause liver enzyme elevations and possibly liver failure. Advise patients to promptly report fatigue, anorexia, right upper abdominal discomfort, dark urine or jaundice .
Myopathy and Rhabdomyolysis
Advise patients that fenofibrate tablets may cause myopathy and rhabdomyolysis. Inform patients that the risk is also increased when taking certain types of medication and they should discuss all medication, both prescription and over the counter, with their healthcare provider. Instruct patients to inform other healthcare providers prescribing a new medication or increasing the dosage of an existing medication that they are taking fenofibrate tablets. Instruct patients to promptly report any unexplained muscle pain, tenderness, or weakness particularly if accompanied by malaise or fever .
Increased Bleeding Risk with Coumarin Anticoagulants
Inform patients that the concomitant use of fenofibrate tablets with coumarin-type anticoagulants may increase the risk of bleeding. …
Warnings & precautions
Do not take this medicine if: Fenofibrate tablets are contraindicated in patients with:
•Severe renal impairment, including those with end-stage renal disease (ESRD) and those receiving dialysis .
•Active liver disease, including those with unexplained persistent liver function abnormalities .
•Pre-existing gallbladder disease .
•Hypersensitivity to fenofibrate, fenofibric acid, or any of the excipients in fenofibrate tablets. Serious hypersensitivity reactions including anaphylaxis and angioedema have been reported with fenofibrate .
Fenofibrate did not reduce cardiovascular disease morbidity or mortality in two large, randomized controlled trials of patients with type 2 diabetes mellitus .
Because of chemical, pharmacological, and clinical similarities between fenofibrates, including fenofibrate tablets; pemafibrate; clofibrate; and gemfibrozil; the findings in 5 large randomized, placebo-controlled clinical trials with these other fibrate drugs may also apply to fenofibrate tablets.
Pemafibrate did not reduce cardiovascular disease morbidity or mortality in a large, randomized, placebo-controlled trial of patients with type 2 diabetes mellitus on background statin therapy .
In the Coronary Drug Project, a large trial conducted from 1,965 to 1,985 in men post myocardial infarction, there was no difference in mortality or nonfatal myocardial infarction between the clofibrate group and the placebo group after 5 years of treatment (NCT00000482).
In a trial conducted by the World Health Organization (WHO) from 1,965 to 1,976, men without known coronary artery disease were treated with placebo or clofibrate for 5 years and followed for an additional 1 year. There was a statistically significant, higher age-adjusted all-cause mortality in the clofibrate group compared with the placebo group (5.70% vs. 3.96%, p ≤ 0.01). …
Fenofibrate side effects
The following serious adverse reactions are described below and elsewhere in the labeling:
•Mortality and coronary heart disease morbidity
•Hepatoxicity
•Myopathy and Rhabdomyolysis
•Increases in Serum Creatinine
•Cholelithiasis
•Increased Bleeding Risk with Coumarin Anticoagulants
•Pancreatitis
•Hematologic Changes
•Hypersensitivity reactions
•Venothromboembolic disease
•Paradoxical Decreases in HDL Cholesterol Levels
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice.
The safety of fenofibrate has been established in adults with hypertriglyceridemia or primary hyperlipidemia based on adequate and well-controlled trials of other formulations of fenofibrate, referenced below as “fenofibrate” . Dosages of fenofibrate used in these trials were comparable to fenofibrate tablets 145 mg per day .
Adverse reactions reported by 2% or more of patients treated with fenofibrate (and greater than placebo) during the double-blind, placebo-controlled trials are listed in Table 1. Adverse reactions led to discontinuation of treatment in 5% of patients treated with fenofibrate and in 3% treated with placebo. Increases in liver function tests were the most frequent events, causing discontinuation of fenofibrate treatment in 1.6% of patients in double-blind trials.
Table 1. …
Drug interactions
Table 2 presents clinically important drug interactions with fenofibrate tablets.
Table 2. Clinically Important Drug Interactions with Fenofibrate Tablets
Statins
Clinical Impact: | Fibrates may cause myopathy when given alone. The risk of myopathy and rhabdomyolysis is increased with concomitant use of fibrates with statins.
Intervention: | Consider if the benefit of using fenofibrate tablets concomitantly with statin therapy outweighs the increased risk of myopathy and rhabdomyolysis. If concomitant use is decided, monitor patients for signs and symptoms of myopathy, particularly during initiation of therapy and during upward dosage titration of statin therapy.
Colchicine
Clinical Impact: | Cases of myopathy and rhabdomyolysis have been reported with concomitant use of colchicine with fenofibrates.
Intervention: | Consider if the benefit of using colchicine concomitantly with fenofibrate tablets outweighs the increased risk of myopathy and rhabdomyolysis. If concomitant use is decided, monitor patients for signs and symptoms of myopathy, particularly during initiation of therapy and during upward dosage titration of colchicine.
Coumarin Anticoagulants
Clinical Impact: | Fibrates may cause potentiation of coumarin-type anticoagulant effects with prolongation of the PT/INR. …
About this medicine
Fenofibrate tablets, USP are a peroxisome proliferator-activated receptor (PPAR) alpha agonist available as tablets for oral administration. Each tablet contains 48 mg or 145 mg of fenofibrate, USP. The chemical name for fenofibrate is 2-[4-(4-chlorobenzoyl) phenoxy]-2-methyl-propanoic acid, 1-methylethyl ester with the following structural formula:
The empirical formula is C20H21O4Cl and the molecular weight is 360.83; fenofibrate is insoluble in water. The melting point is 79 to 82°C. Fenofibrate is a white solid which is stable under ordinary conditions.
Inactive Ingredients
Each tablet contains crospovidone, hypromellose 2910 (3 cps), lactose monohydrate, magnesium stearate, silicified microcrystalline cellulose, sodium lauryl sulfate, and sucrose.
In addition, individual tablets contain:
48 mg tablets
iron oxide yellow, macrogol/PEG 3350, polyvinyl alcohol-part. hydrolyzed, talc, and titanium dioxide.
145 mg tablets
macrogol/PEG 3350, polyvinyl alcohol-part. hydrolyzed, talc, and titanium dioxide.
How it works: The active moiety of fenofibrate tablets is fenofibric acid. …
Source: FDA-approved label via DailyMed (U.S. National Library of Medicine), label set ID 085109a6-f006-44f0-a170-980d8899a365. Read the full official label on DailyMed.
Related medicines
Atorvastatin Metformin Losartan Semaglutide Insulin Glargine Empagliflozin Glipizide Insulin Lispro